List of Excipients in Branded Drug HYDROXOCOBALAMIN

Generic Drugs Containing HYDROXOCOBALAMIN

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	hydroxocobalamin	0591-2888	ACETIC ACID
Actavis Pharma Inc	hydroxocobalamin	0591-2888	METHYLPARABEN
Actavis Pharma Inc	hydroxocobalamin	0591-2888	PROPYLPARABEN
Actavis Pharma Inc	hydroxocobalamin	0591-2888	SODIUM ACETATE ANHYDROUS
Actavis Pharma Inc	hydroxocobalamin	0591-2888	SODIUM CHLORIDE
Actavis Pharma Inc	hydroxocobalamin	0591-2888	WATER

What are the Most Frequently-Used Excipients in HYDROXOCOBALAMIN?

# Of NDCs	Excipient
2	ACETIC ACID
2	METHYLPARABEN
2	PROPYLPARABEN
2	SODIUM ACETATE ANHYDROUS
2	SODIUM CHLORIDE
2	WATER

Hydroxocobalamin Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Hydroxocobalamin has two distinct pharmaceutical markets: injectable cyanide antidote products and vitamin B12 replacement products. The strongest excipient opportunities are in ready-to-use emergency injections, rapid reconstitution systems, preservative-free maintenance products, and oral or intranasal delivery platforms that improve adherence. The principal technical constraints are color instability, light sensitivity, pH control, sterilization, adsorption, dose volume, and compatibility with infusion materials.

What pharmaceutical products contain hydroxocobalamin?

Hydroxocobalamin is a cobalamin form used in prescription injections, cyanide poisoning treatment, and vitamin B12 replacement. Its commercial positioning differs by dosage and route.

Product segment	Typical dose profile	Primary use	Regulatory position	Excipient priority
Cyanokit-type injection	5 g intravenous dose	Suspected cyanide poisoning	FDA-approved prescription drug	Rapid reconstitution, stability, low particulate burden
Hydroxocobalamin injection	1 mg/mL or similar	Vitamin B12 deficiency	Prescription drug, depending on jurisdiction	Preservative-free stability, injection comfort, container compatibility
Intramuscular maintenance product	Low milligram dose	Pernicious anemia and malabsorption	Drug product	Low-volume injection, long shelf life
Oral solid dosage form	Microgram-to-milligram dose	Nutritional supplementation or deficiency	Drug or dietary supplement, depending on claims	Taste, dissolution, light protection
Intranasal product	Microgram-to-milligram dose	B12 replacement or maintenance	Drug product if therapeutic claims are made	Mucoadhesion, spray performance, dose uniformity
Veterinary injection	Species-specific dosing	B12 deficiency and supportive care	Veterinary drug	Cost, multidose packaging, antimicrobial preservation

Cyanokit contains 5 g of hydroxocobalamin as a lyophilized powder for intravenous infusion. The approved product is reconstituted before administration and is supplied with diluent and transfer equipment. Its excipient system is intentionally limited because the product is administered in emergency settings at a high dose [1].

What excipients are used in hydroxocobalamin injections?

The most defensible parenteral excipient strategy is a minimal, preservative-free system with pH and tonicity controls.

Core excipient functions

Function	Candidate excipients	Commercial rationale
Tonicity adjustment	Sodium chloride, mannitol	Controls injection tolerability and reconstitution behavior
pH adjustment	Hydrochloric acid, sodium hydroxide	Establishes hydroxocobalamin solubility and stability range
Bulking agent for lyophilization	Mannitol, sucrose, trehalose	Improves cake structure and handling
Stabilization	Sucrose, trehalose, selected polyols	May reduce degradation during freezing and drying
Surfactancy	Polysorbate 20 or 80, poloxamer 188	Potentially limits surface adsorption, but requires compatibility testing
Chelation or oxidation control	Formulation-specific agents	May reduce trace-metal or oxidative degradation, subject to parenteral safety
Antimicrobial preservation	Benzyl alcohol, phenol, m-cresol	Generally more relevant to multidose products than emergency single-dose products

Cyanokit’s approved presentation uses a lyophilized formulation with a dedicated diluent. The product label states that the supplied diluent is 0.9% sodium chloride injection and permits other compatible intravenous solutions under specified conditions [1]. A commercial developer should not assume that a generic sodium chloride system will reproduce the product’s reconstitution time, cake integrity, color profile, or impurity control.

Why preservative-free formulations are commercially attractive

Preservative-free single-dose packaging is the preferred strategy for emergency intravenous hydroxocobalamin. A 5 g antidote dose is administered under acute conditions, often through central or peripheral intravenous access. The product has no commercial need for repeated withdrawals from the same vial.

Preservatives may create avoidable risks:

• Injection-site irritation.
• Toxicity concerns in neonates and vulnerable patients.
• Compatibility problems with emergency infusion equipment.
• Additional extractables and leachables burden.
• More complex regulatory justification for a high-dose intravenous product.

Multidose hydroxocobalamin products for routine B12 therapy may justify antimicrobial preservation, but the economic value of multidose packaging must be weighed against preservative tolerability and the availability of low-cost single-dose ampoules.

How does hydroxocobalamin stability affect excipient selection?

Hydroxocobalamin is intensely red because of its corrin-ring chromophore. The color is commercially useful for visual identification but creates analytical and manufacturing challenges. A formulation must control light exposure, oxidation, pH drift, degradation products, and adsorption to processing surfaces.

Principal stability risks

1. Light exposure can alter color and chemical integrity.
2. Extreme pH can accelerate degradation or change solubility.
3. Oxygen and trace metals can contribute to oxidative pathways.
4. Freeze-drying can cause collapse, poor reconstitution, or increased residual moisture.
5. Contact with tubing, filters, and bags can affect recovery or create compatibility problems.
6. High-dose solutions can create unusually high excipient and impurity loads after reconstitution.

Recommended development controls include amber or opaque primary packaging, validated photostability testing, low-permeability container systems, and stability-indicating chromatographic methods. The container closure system is part of the product strategy, not a secondary packaging decision.

Lyophilized versus liquid presentations

Attribute	Lyophilized hydroxocobalamin	Ready-to-use liquid
Shelf-life potential	Generally stronger for unstable formulations	Depends heavily on pH and oxygen control
Emergency readiness	Requires reconstitution	Immediate administration
Manufacturing complexity	Higher	Lower if liquid stability is adequate
Shipping	Lower water-related degradation risk	Greater temperature and light sensitivity
Device opportunity	Transfer device, dual-chamber vial	Prefilled syringe, cartridge, infusion bag
Commercial differentiation	Reconstitution speed and kit design	Convenience and reduced preparation error

For a cyanide antidote, lyophilization remains commercially defensible because the product must maintain a long shelf life across hospital, military, industrial, and emergency-response inventories. A ready-to-use liquid could command a premium if it demonstrated materially faster administration and equivalent stability.

What formulations are protected or differentiated by excipients?

Excipients rarely create durable protection by themselves. Commercially meaningful formulation protection usually combines composition, concentration ranges, pH, moisture limits, container closure, lyophilization cycle, reconstitution performance, and impurity profile.

Potential claim categories include:

• Hydroxocobalamin with a defined polyol or disaccharide stabilizer.
• A specified pH range that limits degradation.
• A low-residual-moisture lyophilized cake.
• A ready-to-use liquid with controlled oxygen exposure.
• A dual-chamber presentation containing hydroxocobalamin and diluent.
• A formulation that reconstitutes below a defined time threshold.
• A container system that limits light transmission.
• A composition compatible with a defined infusion bag or tubing material.
• A nasal formulation with a mucoadhesive polymer and controlled spray plume.
• An oral dosage form with improved dissolution or bioavailability.

The strongest formulation claims are performance-linked. A patent that only lists common excipients may face enablement, written-description, obviousness, and freedom-to-operate challenges. Claims tied to unusual stability data, reconstitution speed, impurity reduction, or device compatibility are more commercially useful.

When does hydroxocobalamin lose exclusivity?

Hydroxocobalamin is an established active ingredient, so composition-of-matter exclusivity is generally not the central commercial barrier. Generic competition is more likely to target injectable dosage forms, manufacturing efficiency, packaging, and supply reliability.

Exclusivity category	Relevance to hydroxocobalamin
New chemical entity exclusivity	Limited relevance for an established active ingredient
Orphan-drug exclusivity	Potentially relevant to a cyanide-antidote indication if the qualifying product and designation apply
Pediatric exclusivity	Product-specific and dependent on FDA action
Formulation patents	Relevant to lyophilization, stabilizers, reconstitution, and containers
Method-of-use patents	Possible for specific dosing, administration, or clinical uses
Device patents	Relevant to transfer systems, dual-chamber containers, and prefilled delivery
Generic approval	Major risk for routine hydroxocobalamin injections
Biosimilar pathway	Not applicable; hydroxocobalamin is a chemically defined small molecule

Cyanokit is regulated as a drug, not a biologic. Biosimilar competition is therefore not the relevant framework. The main regulatory threat is abbreviated new drug application competition or a competing full NDA, depending on the product and reference listing.

What is the FDA regulatory status of hydroxocobalamin?

The FDA approved Cyanokit for the treatment of known or suspected cyanide poisoning in adults and pediatric patients [1]. The product is administered intravenously after reconstitution. FDA-approved hydroxocobalamin injection products also exist for vitamin B12 replacement, although labeling, strength, excipients, and approved indications vary by manufacturer and jurisdiction.

A developer should separate three regulatory pathways:

Cyanide antidote

A new injectable antidote would face a high evidentiary and manufacturing standard. Product performance must address:

• Rapid availability in emergency departments and ambulances.
• Reconstitution or administration time.
• Sterility assurance.
• Visible particles and particulate control.
• Dose delivery from the vial.
• Compatibility with infusion systems.
• Color interference with laboratory tests.
• Inventory stability under emergency-storage conditions.

Vitamin B12 injection

A conventional hydroxocobalamin injection can compete through lower cost, fewer injections, preservative-free packaging, smaller injection volume, or a differentiated supply chain. The clinical benefit of hydroxocobalamin over cyanocobalamin may be relevant in certain markets because hydroxocobalamin has longer tissue retention and is commonly used at extended dosing intervals.

Oral, sublingual, and nasal products

These routes require a new formulation and, where therapeutic claims are made, drug approval. Supplement positioning may reduce development costs but limits permissible disease and deficiency claims in the United States. Absorption data, dose uniformity, stability, and consumer adherence determine the commercial value.

What patent litigation and Paragraph IV risks affect hydroxocobalamin?

Paragraph IV risk is likely to be concentrated around branded injectable products with listed patents covering formulation, container systems, or methods of use. The active ingredient itself is unlikely to provide a modern blocking patent position.

The principal litigation scenarios are:

1. A generic challenges formulation or device patents listed for a reference product.
2. The branded company alleges infringement after receiving a Paragraph IV notice.
3. The generic argues that the listed patent does not claim the approved product or that the claims are invalid.
4. The parties settle with an authorized-generic, license, or delayed-entry arrangement.
5. A competitor launches at risk after patent invalidation or a noninfringement position.

Orange Book status is product-specific. A patent conclusion cannot be drawn from the active ingredient name alone. The relevant analysis requires review of the current FDA Orange Book entry, listed patents, pediatric extensions, regulatory exclusivity, and litigation records [2]. For Cyanokit, the commercial assessment should focus on whether any active listed patents cover the approved presentation rather than hydroxocobalamin generally.

How strong is the hydroxocobalamin patent estate?

The patent estate is likely to be stronger around product architecture than around the molecule.

Estate component	Relative strength	Reason
Hydroxocobalamin molecule	Low	Long-established active ingredient
Basic injectable solution	Low to moderate	Many conventional excipients are predictable
High-dose lyophilized antidote	Moderate	Reconstitution, stability, and manufacturing data can support narrower claims
Dual-chamber or rapid-reconstitution device	Moderate to strong	Device integration may create practical differentiation
Light-protective packaging	Low to moderate	Often vulnerable to obviousness challenges unless tied to performance
Intranasal delivery	Moderate	Device and mucoadhesion claims may create new barriers
Long-acting depot formulation	Potentially strong	Requires non-obvious release profile and supporting data
Manufacturing process	Moderate	Process claims can protect yield, impurity control, or scale-up
Method of use	Variable	Strength depends on clinical differentiation and claim scope

Manufacturing know-how may be more valuable than publicly visible patents. Control of hydroxocobalamin purity, color consistency, lyophilization cycle, residual moisture, and large-scale sterile filling can delay competitors even when patent protection is limited.

What commercial opportunities exist for hydroxocobalamin excipients?

1. Ready-to-use emergency injection

A ready-to-use liquid or prefilled system could reduce preparation steps associated with a lyophilized vial. The opportunity is strongest where emergency departments, ambulances, military units, industrial sites, and stockpiling agencies value faster administration.

The barriers are substantial: long-term liquid stability, container compatibility, high-dose viscosity, oxygen control, and shipping conditions. A dual-chamber syringe or vial may offer a more practical compromise than a conventional prefilled liquid.

2. Faster-reconstituting lyophilized product

A reformulated lyophilized product could compete through:

• Shorter reconstitution time.
• Reduced foaming.
• Lower residual moisture.
• Improved cake appearance.
• Fewer transfer steps.
• Compatibility with standard infusion bags.
• Reduced preparation error.

This is a lower-risk development path than a fully liquid product because lyophilization is already established for the high-dose antidote use case.

3. Extended-interval B12 injection

Hydroxocobalamin’s pharmacokinetic profile supports maintenance products that reduce injection frequency. Excipients can support low-volume, high-concentration intramuscular products, although viscosity and injection-site tolerability limit concentration increases.

A differentiated product could use a depot vehicle, in situ gel, microsphere, or slowly dissolving suspension. Such products may qualify for formulation and method-of-use protection if they produce a clinically relevant reduction in dosing frequency.

4. Intranasal hydroxocobalamin

Intranasal delivery offers a needle-free option for maintenance therapy. Candidate excipient classes include mucoadhesive polymers, isotonic buffers, humectants, and absorption enhancers. The formulation must control spray pattern, droplet size, viscosity, microbial quality, and dose uniformity.

The commercial opportunity is strongest for patients who avoid injections. The regulatory burden includes local tolerability, nasal deposition, pharmacokinetics, and consistency across devices.

5. Oral and sublingual products

Oral products have the largest potential market but face the greatest price competition. Excipients can improve tablet disintegration, dissolution, taste, moisture protection, and dose uniformity. Sublingual and orally disintegrating products can be positioned around convenience, but superiority over conventional oral B12 products must be demonstrated rather than assumed.

6. Veterinary products

Veterinary hydroxocobalamin injections and oral products may support a lower-cost, high-volume segment. Multidose vials and antimicrobial preservation may be commercially relevant, but the formulation must account for repeated puncture, storage after opening, and species-specific administration practices.

How does hydroxocobalamin compare with cyanocobalamin?

Attribute	Hydroxocobalamin	Cyanocobalamin
Main clinical positioning	Cyanide antidote and B12 replacement	Primarily B12 replacement
Injection interval	Can support extended-interval dosing	Often requires more frequent maintenance
Antidote use	Established FDA-approved use	Not used as the standard cyanide antidote
Formulation complexity	High for 5 g antidote dose	Generally lower for vitamin products
Market competition	Branded antidote plus generic B12 products	Broad generic and supplement competition
Excipient opportunity	Emergency delivery and depot systems	Cost, oral delivery, and adherence
Patent opportunity	Product and device focused	Mostly formulation, delivery, and use focused

Hydroxocobalamin has greater potential for premium emergency products. Cyanocobalamin has a broader low-cost replacement market and more intense commodity competition.

What generic launch risks exist?

Generic launch risk is highest for standard hydroxocobalamin injections used in B12 deficiency. A generic manufacturer can compete through a conventional sterile injectable formulation if it can match the reference product’s strength, route, quality attributes, and labeling requirements.

Cyanide-antidote competition is more difficult because the dose is unusually high and the product requires a validated reconstitution process, specialized packaging, and emergency-use manufacturing capacity. Generic entry may still occur, but the technical and commercial barriers are greater than for a 1 mg/mL vitamin injection.

The most credible launch scenarios are:

• Low-price generic vitamin B12 injection.
• Authorized generic or licensed alternative to a branded antidote.
• Hospital-focused ready-to-use product.
• Premium prefilled emergency presentation.
• Extended-interval depot injection.
• Intranasal maintenance product.

Key Takeaways

• Hydroxocobalamin has separate commercial markets in cyanide poisoning and vitamin B12 replacement.
• The best excipient strategy for a high-dose antidote is minimal, preservative-free, lyophilized, and optimized for rapid reconstitution.
• Sodium chloride, mannitol, sucrose, trehalose, pH adjusters, and selected surfactants are the main formulation tools, subject to compatibility and stability data.
• Ready-to-use liquid products offer convenience but face significant stability and packaging barriers.
• Formulation and device patents are more commercially relevant than molecule patents.
• Generic risk is high for routine hydroxocobalamin injections and lower for complex high-dose antidote presentations.
• Biosimilar risk does not apply because hydroxocobalamin is a small-molecule drug.
• Extended-interval injections, intranasal products, dual-chamber systems, and improved lyophilized kits are the strongest commercial opportunities.
• Manufacturing control, sterile filling capacity, impurity management, and emergency inventory reliability may create barriers beyond patent protection.
• Current Orange Book listings, patent claims, and Paragraph IV litigation must be evaluated at the individual product level.

FAQs

Can hydroxocobalamin be formulated without preservatives?

Yes. Preservative-free single-dose injections are technically and commercially appropriate, particularly for intravenous antidote products and sensitive patient populations.

Which excipient is most important for a lyophilized hydroxocobalamin product?

Mannitol or a related bulking agent can improve cake structure, but the optimal excipient depends on the hydroxocobalamin concentration, freezing cycle, residual moisture target, and reconstitution requirements.

Is hydroxocobalamin suitable for a prefilled syringe?

Potentially, but the product requires validated liquid stability, light protection, syringe-material compatibility, particulate control, and reliable dose delivery over the proposed shelf life.

Can excipients improve hydroxocobalamin absorption through the nose?

Mucoadhesive polymers and absorption-enhancing systems may improve residence time or uptake, but they also create local tolerability and regulatory requirements.

Is a hydroxocobalamin depot injection commercially protectable?

Potentially. A depot product may support composition, release-profile, manufacturing-process, and method-of-use claims if the formulation demonstrates non-obvious clinical or pharmacokinetic performance.

References

1. U.S. Food and Drug Administration. (2021). Cyanokit (hydroxocobalamin for injection) prescribing information. FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

4. National Library of Medicine. (n.d.). Hydroxocobalamin injection drug labeling. DailyMed.

5. U.S. Food and Drug Administration. (2019). Q1A(R2) stability testing of new drug substances and products. FDA.